股本结构
单位：万股
| 公告日期 | 2025-11-13 | 2025-11-14 | 2025-05-14 | 2025-03-20 | 2025-03-20 | 2024-11-12 |
|---|---|---|---|---|---|---|
| 证券总股本 | 7503.43 | 5993.22 | 5988.18 | 5988.18 | 5978.93 | 4118.31 |
| 普通股本 | 7503.43 | 5993.22 | 5988.18 | 5988.18 | 5978.93 | 4118.31 |
| 优先股 | 11.45 | 未披露 | 11.45 | 未披露 | 11.45 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-13 | 2025-11-07 | 2025-03-31 | 2025-03-17 | 2024-12-31 | 2024-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-13 | 7503.43 | 11.45 |
更多>>
Common Stock offered 15,152,485 shares by the company
|
2025-11-13 |
| 2025-11-14 | 5993.22 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-05-14 | 5988.18 | 11.45 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
Stock option exercise
|
2025-03-31 |
| 2025-03-20 | 5988.18 | 未披露 | 定期报告 | 2025-03-17 |
| 2025-03-20 | 5978.93 | 11.45 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock and pre-funded warrants in connection with the 2024 Securities Purchase Agreement, net of issuance costs
Issuance of common stock with the completion of the Second Closing and Third Closing in connection with 2023 Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock and pre-funded warrants in connection with 2024 Underwritten Offering, net of issuance costs.
Stock Option Exercise
|
2024-12-31 |
| 2024-10-30 | 5973.93 | 未披露 |
更多>>
Common stock offered 18,356,173 shares by the company
|
2024-10-30 |
| 2024-10-01 | 4138.31 | 未披露 |
更多>>
On October 1, 2024 the company issued 200,000 common shares
|
2024-10-01 |
| 2024-11-12 | 4118.31 | 11.45 |
更多>>
On September 30, 2024 the company issued 1,527,400 common shares
|
2024-09-30 |
| 2024-08-19 | 3965.57 | 未披露 | 定期报告 | 2024-08-14 |
| 2024-08-19 | 3850.66 | 11.45 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock and pre-funded warrants in connection with 2024 Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with exercise of pre-funded warrants
|
2024-06-30 |
| 2024-05-15 | 3850.66 | 未披露 | 定期报告 | 2024-05-10 |
| 2024-05-15 | 2481.31 | 11.45 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with exercise of pre-funded warrants
|
2024-03-31 |
| 2024-03-28 | 2481.31 | 未披露 | 定期报告 | 2024-03-25 |
| 2024-03-28 | 2421.31 | 11.45 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with conversion of X non-voting convertible preferred stock
Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with vesting of restricted stock units
|
2023-12-31 |
| 2023-11-09 | 2419.81 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-09 | 2354.51 | 11.45 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with exercise of pre-funded warrants
|
2023-09-30 |
| 2023-08-10 | 2354.51 | 未披露 | 定期报告 | 2023-08-08 |
| 2023-08-10 | 2304.39 | 11.45 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock
Issuance of common stock in connection with conversion of X non-voting convertible preferred stock
|
2023-06-30 |
| 2023-05-11 | 2250.70 | 未披露 | 定期报告 | 2023-05-10 |
| 2023-03-30 | 1377.68 | 12.42 |
更多>>
From December 31, 2021 To December 31, 2022
Cancellation of common stock in connection with exchange for X1 non-voting convertible preferred stock
Issuance of common stock in connection with vesting of restricted stock units
|
2022-12-31 |
| 2022-05-12 | 1375.68 | 12.42 |
更多>>
From December 31, 2021 to March 31, 2022
Cancellation of common stock in connection with exchange for X1 non-voting convertible preferred stock
|
2022-03-31 |
| 2022-03-24 | 1430.68 | 未披露 | 定期报告 | 2022-03-22 |
| 2022-01-13 | 1375.68 | 11.80 | 定期报告 | 2022-01-11 |
| 2021-11-12 | 1430.68 | 11.43 |
更多>>
From June 30, 2021 to September 30, 2021
Stock options exercised
|
2021-09-30 |
| 2021-05-14 | 1430.66 | 11.43 |
更多>>
From December 31, 2020 to March 31, 2021
Cancellation of common stock in connection with exchange for preferred stock
Cancellation of common stock in connection with exchange for warrants
|
2021-03-31 |
| 2021-03-31 | 1430.66 | 未披露 | 定期报告 | 2021-03-23 |
| 2021-03-31 | 1516.04 | 10.81 |
更多>>
from December 31, 2019 to December 31, 2020
Issuance of common stock in connection with conversion of Series X preferred stock
Issuance of common stock in connection with conversion of Series X1 preferred stock
Cancellation of common stock in connection with exchange for preferred stock
Issuance of preferred stock in connection with acquisition
Issuance of preferred stock in connection with PIPE transaction, net of issuance costs
Issuance of common stock in connection with PIPE transaction, net of issuance costs
Issuance of common stock in connection with exercise of warrants, net of issuance costs
Issuance of common stock in connection with vesting of restricted stock units
Issuance of common stock in connection with acquisition
Cancellation of common stock in connection with reverse split
|
2020-12-31 |
| 2020-12-22 | 1516.04 | 600.39 | 定期报告 | 2020-12-22 |
| 2020-11-20 | 143.63 | 33.91 | 定期报告 | 2020-11-17 |
| 2020-11-16 | 143.13 | 未披露 | 定期报告 | 2020-11-13 |
| 2020-11-20 | 127.46 | 未披露 | 定期报告 | 2020-10-16 |
| 2020-10-02 | 107.69 | 未披露 |
更多>>
a 1:18 shares split
|
2020-10-05 |
| 2020-08-14 | 1938.46 | 未披露 | 定期报告 | 2020-08-11 |
| 2020-08-14 | 1937.96 | 0.05 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock in connection with conversion of preferred stock
Issuance of common stock in connection with vesting of restricted stock units
|
2020-06-30 |
| 2020-05-15 | 1606.96 | 0.38 |
更多>>
From December 31, 2019 to March 31, 2020
Cancellation of common stock in connection with exchange for preferred stock
Issuance of common stock in connection with exercise of warrants, net of issuance costs
|
2020-03-31 |
| 2020-03-25 | 1606.96 | 未披露 | 定期报告 | 2020-03-01 |
| 2020-03-17 | 1296.73 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common stock at-the-market, net of issuance costs
Issuance of common stock and warrants in registered direct offering, net of issuance costs
Issuance of common stock in connection with vesting of restricted stock units
Cancellation of common stock
|
2019-12-31 |
| 2019-11-13 | 1296.73 | 未披露 | 定期报告 | 2019-11-11 |
| 2019-08-13 | 1297.49 | 未披露 |
更多>>
From December 31, 2018 to June 30, 2019
Issuance of common stock at-the-market, net of issuance costs
Issuance of common stock and warrants in registered direct offering, net of issuance costs
Issuance of common stock in connection with vesting of restricted stock units
|
2019-06-30 |
| 2019-05-14 | 1289.65 | 未披露 | 定期报告 | 2019-05-10 |
| 2019-05-02 | 1287.13 | 未披露 | 定期报告 | 2019-05-02 |
| 2019-05-14 | 944.74 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of common stock at-the-market,net of issuance costs
|
2019-03-31 |
| 2019-03-28 | 943.42 | 未披露 | 定期报告 | 2019-03-22 |
| 2019-03-28 | 942.21 | 未披露 |
更多>>
From December 31, 2017 to September 30,2018
Issuance of common stock at-the-market,net of issuance costs
Exercise of options
|
2018-09-30 |
| 2018-08-07 | 942.21 | 未披露 | 定期报告 | 2018-08-03 |
| 2018-05-11 | 940.70 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-04-02 | 940.70 | 未披露 | 定期报告 | 2018-03-23 |
| 2018-04-02 | 711.04 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock for cashless exercise of warrants
Conversion of convertible note and accrued interest to common stock
Receipt on account of contingently convertible stock
Issuance of common stock in connection with Reverse Merger
Issuance of common stock for cash
Issuance of common stock at-the-market,net of issuance costs of $24
Cancellation of fractional common stock
Issuance of preferred stock for exercise of warrants
|
2017-12-31 |
| 2017-11-08 | 708.54 | 未披露 | 定期报告 | 2017-11-06 |
| 2017-11-08 | 694.31 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-09 | 694.31 | 未披露 |
更多>>
Otic Pharma, Ltd., a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced the close of the previously announced combination with Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI, through May 10, 2017).In connection with the previously announced transaction, Tokai changed its name to Novus Therapeutics, Inc. and effected a 1-for-9 reverse split of its common stock.The common stock is expected to commence trading on a post-reverse split basis upon the opening of trading on May 11, 2017 on the NASDAQ Capital Market under the symbol "NVUS."
|
2017-08-04 |
| 2017-08-09 | 694.38 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-10 | 700.00 | 未披露 |
更多>>
Otic Pharma, Ltd., a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced the close of the previously announced combination with Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI, through May 10, 2017).In connection with the previously announced transaction, Tokai changed its name to Novus Therapeutics, Inc. and effected a 1-for-9 reverse split of its common stock.The common stock is expected to commence trading on a post-reverse split basis upon the opening of trading on May 11, 2017 on the NASDAQ Capital Market under the symbol "NVUS."
|
2017-05-11 |
| 2017-03-03 | 2264.17 | 未披露 |
更多>>
From December 31, 2015 to September 30, 2016
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock units
|
2016-09-30 |
| 2016-05-10 | 2263.48 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-10 | 2262.52 | 未披露 | 定期报告 | 2016-02-29 |
| 2016-03-10 | 2259.71 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock units
|
2015-12-31 |
| 2015-11-10 | 2258.47 | 未披露 | 定期报告 | 2015-10-31 |
| 2015-08-12 | 2254.77 | 未披露 | 定期报告 | 2015-07-31 |
| 2015-05-12 | 2241.36 | 未披露 | 定期报告 | 2015-04-30 |
| 2015-04-30 | 2240.34 | 未披露 | 定期报告 | 2015-04-23 |
| 2014-11-13 | 2238.17 | 未披露 | 定期报告 | 2014-11-10 |
| 2014-09-18 | 2184.17 | 未披露 |
更多>>
a 1-for-10.47 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our redeemable convertible preferred stock, which became effective on August 29, 2014
|
2014-09-17 |
| 2014-09-02 | 50.16 | 15558.61 |
更多>>
On August 29, 2014, the Company effected a 1-for-10.47 reverse stock split of its issued and outstanding shares of common stock
|
2014-09-02 |
| 2014-08-11 | 525.15 | 15558.61 |
更多>>
from December 31, 2013 to June 30, 2014
Issuance of common stock upon exercise of stock options
|
2014-06-30 |
Common Stock offered 15,152,485 shares by the company
From December 31, 2024 to March 31, 2025
Issuance of common stock in connection with vesting of restricted stock units
Stock option exercise
From December 31, 2023 to December 31, 2024
Issuance of common stock and pre-funded warrants in connection with the 2024 Securities Purchase Agreement, net of issuance costs
Issuance of common stock with the completion of the Second Closing and Third Closing in connection with 2023 Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock and pre-funded warrants in connection with 2024 Underwritten Offering, net of issuance costs.
Stock Option Exercise
Common stock offered 18,356,173 shares by the company
On October 1, 2024 the company issued 200,000 common shares
On September 30, 2024 the company issued 1,527,400 common shares
From March 31, 2024 to June 30, 2024
Issuance of common stock and pre-funded warrants in connection with 2024 Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with exercise of pre-funded warrants
From December 31, 2023 to March 31, 2024
Issuance of common stock in connection with exercise of pre-funded warrants
From December 31, 2022 to December 31, 2023
Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with conversion of X non-voting convertible preferred stock
Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock
Issuance of common stock in connection with exercise of pre-funded warrants
Issuance of common stock in connection with vesting of restricted stock units
From June 30, 2023 to September 30, 2023
Issuance of common stock in connection with exercise of pre-funded warrants
From March 31, 2023 to June 30, 2023
Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs
Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock
Issuance of common stock in connection with conversion of X non-voting convertible preferred stock
From December 31, 2021 To December 31, 2022
Cancellation of common stock in connection with exchange for X1 non-voting convertible preferred stock
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2021 to March 31, 2022
Cancellation of common stock in connection with exchange for X1 non-voting convertible preferred stock
From June 30, 2021 to September 30, 2021
Stock options exercised
From December 31, 2020 to March 31, 2021
Cancellation of common stock in connection with exchange for preferred stock
Cancellation of common stock in connection with exchange for warrants
from December 31, 2019 to December 31, 2020
Issuance of common stock in connection with conversion of Series X preferred stock
Issuance of common stock in connection with conversion of Series X1 preferred stock
Cancellation of common stock in connection with exchange for preferred stock
Issuance of preferred stock in connection with acquisition
Issuance of preferred stock in connection with PIPE transaction, net of issuance costs
Issuance of common stock in connection with PIPE transaction, net of issuance costs
Issuance of common stock in connection with exercise of warrants, net of issuance costs
Issuance of common stock in connection with vesting of restricted stock units
Issuance of common stock in connection with acquisition
Cancellation of common stock in connection with reverse split
a 1:18 shares split
From March 31, 2020 to June 30, 2020
Issuance of common stock in connection with conversion of preferred stock
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2019 to March 31, 2020
Cancellation of common stock in connection with exchange for preferred stock
Issuance of common stock in connection with exercise of warrants, net of issuance costs
From December 31, 2018 to December 31, 2019
Issuance of common stock at-the-market, net of issuance costs
Issuance of common stock and warrants in registered direct offering, net of issuance costs
Issuance of common stock in connection with vesting of restricted stock units
Cancellation of common stock
From December 31, 2018 to June 30, 2019
Issuance of common stock at-the-market, net of issuance costs
Issuance of common stock and warrants in registered direct offering, net of issuance costs
Issuance of common stock in connection with vesting of restricted stock units
From December 31, 2018 to March 31, 2019
Issuance of common stock at-the-market,net of issuance costs
From December 31, 2017 to September 30,2018
Issuance of common stock at-the-market,net of issuance costs
Exercise of options
from December 31, 2016 to December 31, 2017
Issuance of common stock for cashless exercise of warrants
Conversion of convertible note and accrued interest to common stock
Receipt on account of contingently convertible stock
Issuance of common stock in connection with Reverse Merger
Issuance of common stock for cash
Issuance of common stock at-the-market,net of issuance costs of $24
Cancellation of fractional common stock
Issuance of preferred stock for exercise of warrants
Otic Pharma, Ltd., a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced the close of the previously announced combination with Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI, through May 10, 2017).In connection with the previously announced transaction, Tokai changed its name to Novus Therapeutics, Inc. and effected a 1-for-9 reverse split of its common stock.The common stock is expected to commence trading on a post-reverse split basis upon the opening of trading on May 11, 2017 on the NASDAQ Capital Market under the symbol "NVUS."
Otic Pharma, Ltd., a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced the close of the previously announced combination with Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI, through May 10, 2017).In connection with the previously announced transaction, Tokai changed its name to Novus Therapeutics, Inc. and effected a 1-for-9 reverse split of its common stock.The common stock is expected to commence trading on a post-reverse split basis upon the opening of trading on May 11, 2017 on the NASDAQ Capital Market under the symbol "NVUS."
From December 31, 2015 to September 30, 2016
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock units
From December 31, 2014 to December 31, 2015
Issuance of common stock upon exercise of stock options
Issuance of common stock upon vesting of restricted stock units
a 1-for-10.47 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our redeemable convertible preferred stock, which became effective on August 29, 2014
On August 29, 2014, the Company effected a 1-for-10.47 reverse stock split of its issued and outstanding shares of common stock
from December 31, 2013 to June 30, 2014
Issuance of common stock upon exercise of stock options